Gene

RICTOR

RPTOR independent companion of MTOR complex 2

Explore in graph →CI-GENE-00023548HGNC:28611 ENSG00000164327 NCBI 253260 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RICTOR Amplification4
Onatasertib + SapanisertibSubstitutes	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2

Cohorts

Alteration frequency by cohort (107)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved107 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Sarcoma (MSK, 2026) lms_msk_2026	unmapped	Ssm	7	41	17.1%	20	cbioportal

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.
· Cancer Discov · 2015 · PMID 26370156 · validated civic_curation pubmed